



Study Title:	Treatment trial for systemic light-chain amyloidosis
Scientific Title:	ECOG E4A08 – Phase III Randomized Study of Melphalan and Dexamethasone With Versus Without Bortezomib in Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Department and/or Specialty:	Oncology-Hematology-Amyloidosis
Investigator:	Michael Thompson, MD, PhD
Contact Information:	Chanda Miller 262-928-5539
<p>Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of plasma cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving melphalan together with dexamethasone is more effective with or without bortezomib in treating systemic amyloidosis.</p> <p>This randomized phase III trial is studying melphalan and dexamethasone to see how well they work with or without bortezomib in treating patients with previously untreated systemic amyloidosis.</p>	



PROHEALTH CARE
RESEARCH INSTITUTE